Video summary

Anmol Ganjoo vs Rahul Mehta | The One Pharma Bet To Make Now | The BroadView with Nikunj Dalmia

Main summary

Key takeaways

Finance

Finance-focused summary (pharma/healthcare investing debate)

Core debate

The two fund managers make very different bets on where to make money in Indian pharma and healthcare:

  • Anmol Ganju: invests in drug manufacturers (pharma stock selection).
  • Rahul Mehta: invests in the healthcare ecosystem (hospitals, distribution/logistics, healthcare-related platforms), aiming to benefit from broader healthcare spend growth.

Anmol Ganju’s pharma-stock framework (step-by-step)

He describes a “simple playbook” for selecting pharma stocks:

  1. Buy stocks that have spent some time in “wilderness” (a period of underperformance / depressed sentiment).

  2. Invest where earnings are at an inflection point (a turning point toward acceleration).

  3. Choose cases where a regulatory tailwind is about to pick up (improving regulation likely supports operations).

Timing / sentiment cue

  • Buy when street excitement is about to get negative—a contrarian setup just before pessimism intensifies.

Specific tickers/companies mentioned (and why)

Aurobindo Pharma (manufacturer bet) — “close counterpart”

  • Valuation: “valuation multiples are still significantly cheap.”
  • Key tailwind: currency depreciation benefits the company “immensely.”
  • Capital cycle: after 4–5 years of heavy investment, returns are expected as investment converts into revenues and EBITDA.

  • Balance sheet / profitability milestone: described as “probably the first time… net cash positive” after a long investment phase (Ganju notes looking back over 15–20 years as part of his historical tracking, as stated in his context).

  • Recommendation framing: an “extremely powerful construct” for generating “meaningful alpha.”

Granules (manufacturer bet) — “turned the corner”

  • Past situation: ~4 years of close to flat earnings, plus problems with the regulator.
  • Business transformation:
    • shift from “large volume products” toward an ADHD portfolio
    • benefit from a CDMO angle (“nice CDMO play”)
  • Earnings outlook: believes next ~3 years of earnings could potentially double.
  • Market positioning / ownership: “reasonable under ownership” with “a lot of disbelief.”
  • Promoter alignment: promoters increased stake by 10% (“doubled down their bet”).
  • Scale: market cap referenced as about ₹15,000–20,000 crore (specifically ~₹17,000 crore after infusion).
  • Thesis: opportunity for “alpha,” with strong returns expected “in my view.”

VR Sequent (animal health) — growth and price performance

  • Sector thesis: animal health is “promising.”
  • Company: VR Sequent (Hyderabad-based).
  • Expected performance: claims meaningful earnings growth and price performance over the next 3 years.
  • Context: mentions complex corporate history (multiple iterations of capital structure, management control, merger/demerger), but says it is “set.”

Rahul Mehta’s ecosystem bet (how it works)

Rahul’s thesis is that healthcare growth flows through the delivery and infrastructure layer, not only manufacturers:

  • Hospitals
  • Distributors
  • Healthcare logistics

Rationale: benefits from a “per capita jump” in healthcare spending (macro driver).

Specific companies/investments mentioned by Rahul Mehta

KIMS Hospital (hospital bet)

  • Location: Hyderabad, expanding rapidly.
  • Doctor retention mechanism: provides equity to doctors, extends via structures likened to ESOPs to doctors, with buyback over time.
  • Expansion: “gone beyond… down to Kerala.”
  • Ownership point: Rahul’s fund/portfolio “now own a hospital called KIMS Hospital.”

Entero Pharma (healthcare logistics / distribution)

  • Business description: transports medicines from factories to retail, and delivers for some online businesses.
  • Thesis positioning: adds “element of e-commerce” exposure within healthcare logistics.
  • Role in portfolio: explicitly framed as a “third investment.”

Mankind Pharma (weight-loss drug theme + generics)

  • Rahul highlights a theme beyond generics: investment in a weight-loss drug, with the view that weight loss may have a bigger societal impact than AI. (This is presented as a thematic framing rather than a strict valuation metric.)

  • Framed as his fourth investment.

Instruments/sectors/tickers explicitly named

Tickers/companies:

  • Aurobindo Pharma
  • Granules
  • VR Sequent
  • KIMS Hospital (hospital operator; not clearly labeled as a listed ticker in the subtitles)
  • Entero Pharma
  • Mankind Pharma

Sector themes (non-tickers):

  • pharma manufacturing
  • animal health
  • hospitals
  • healthcare logistics
  • distribution
  • weight-loss drugs
  • CDMO
  • ADHD portfolio
  • currency depreciation

Key numbers & timelines explicitly mentioned

Anmol Ganju

  • 4–5 years: capital block under investment; expected to convert into revenues and EBITDA.
  • 15–20 years: stated as his long review horizon (tracking context for Aurobindo).
  • Granules:
    • ~4 years of close to flat earnings
    • next ~3 years earnings could “potentially double”
    • promoter stake increase: +10%
    • market cap reference: ~₹15,000–20,000 crore (specifically ~₹17,000 crore after infusion)

Rahul Mehta

  • Next 3 years: expected growth/price performance for VR Sequent (as referenced in the timeline framing).

General macro

  • “Per capita jump” in healthcare spending (no numeric value given).

Explicit cautions / uncertainty signals

  • The “contrarian” element implies timing sensitivity: buy when sentiment turns negative (contrarian risk can be timing-sensitive).
  • For Granules, past regulatory problems and “disbelief” are acknowledged, but the view is to look past them because of business transformation and promoter action.
  • No explicit “not financial advice” disclaimer is present in the provided subtitles excerpt.

Disclosures / disclaimer

  • None explicitly stated in the provided subtitles excerpt.

Presenters/sources mentioned

  • Anmol Ganju
  • Rahul Mehta
  • Nikunj Dalmia (show host: “The BroadView with Nikunj Dalmia”)

Original video